SCHEMBL17064036

SCHEMBL17064036

CCc1ncccc1C(=N)NO

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.38
PDE4A P27815 1/20 0.37
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 2/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
TDP1 Q9NUW8 2/20 0.35
MAPT P10636 2/20 0.33
PKM P14618 1/20 0.33
MAPK1 P28482 1/20 0.32
HTT P42858 2/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
CHIA Q9BZP6 1/20 0.32
NPC1 O15118 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1460028 0.86 P2RX7 (0.46) P2RX7PDE4AALDH1A1KDM4EHPGD
SCHEMBL5056591 0.81 ALDH1A1 (0.41) P2RX7ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL19902793 0.81 ALDH1A1 (0.38) P2RX7PDE4AALDH1A1KDM4EHPGD
SCHEMBL11868039 0.81 P2RX7 (0.47) P2RX7ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL19902734 0.80 KDM4E (0.49) ALDH1A1KDM4EHPGDL3MBTL1MAPT
SCHEMBL20587559 0.77 KDM4E (0.36) P2RX7ALDH1A1KDM4EL3MBTL1TDP1
SCHEMBL19902738 0.77 RAB9A (0.46) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL17064041 0.76 NPC1 (0.51) ALDH1A1HPGDL3MBTL1MAPTMAPK1
SCHEMBL16161582 0.76 KDM4E (0.48) P2RX7ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL19902747 0.76 ATM (0.46) ALDH1A1KDM4EHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2906553-B1 OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2019-06-26 EP disclosed
US-9493446-B2 Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2016-11-15 US disclosed
US-20150252032-A1 OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2015-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252032-A1 OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES HCRTR2, HCRTR1, OXTR P2RX7 339/4885PDE4A 3279/4885ALDH1A1 1086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.